GSK (LON:GSK) Receives Underweight Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their underweight rating on shares of GSK (LON:GSK) in a report issued on Tuesday, MarketBeat.com reports.

Separately, Berenberg Bank reduced their price target on GSK from GBX 1,820 ($22.39) to GBX 1,600 ($19.69) and set a “buy” rating for the company in a research note on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.22).

GSK Trading Down 0.8 %

Shares of GSK stock opened at GBX 1,349.50 ($16.61) on Tuesday. GSK has a 12-month low of GBX 1,282.50 ($15.78) and a 12-month high of GBX 1,823.50 ($22.44). The firm has a 50 day moving average price of GBX 1,352.59 and a two-hundred day moving average price of GBX 1,480.33. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. The company has a market capitalization of £55.06 billion, a PE ratio of 1,194.25, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK Dividend Announcement

The business also recently disclosed a dividend, which was paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th were issued a GBX 15 ($0.18) dividend. The ex-dividend date of this dividend was Thursday, November 14th. This represents a yield of 1.03%. GSK’s dividend payout ratio is presently 5,309.73%.

Insider Transactions at GSK

In other news, insider Jonathan Symonds purchased 1,500 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was bought at an average price of GBX 1,315 ($16.18) per share, with a total value of £19,725 ($24,270.95). In the last three months, insiders have purchased 8,658 shares of company stock valued at $11,950,792. 1.61% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.